C

Cuorips Inc
TSE:4894

Watchlist Manager
Cuorips Inc
TSE:4894
Watchlist
Price: 4 740 JPY 0.42% Market Closed
Market Cap: 38.1B JPY
Have any thoughts about
Cuorips Inc?
Write Note

Gross Margin
Cuorips Inc

48.9%
Current
49%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
48.9%
=
Gross Profit
15.1m
/
Revenue
31m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
JP
Cuorips Inc
TSE:4894
38B JPY
49%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
315.2B USD
67%
US
Amgen Inc
NASDAQ:AMGN
141.9B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36B EUR
89%
Country JP
Market Cap 38B JPY
Gross Margin
49%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 315.2B USD
Gross Margin
67%
Country US
Market Cap 141.9B USD
Gross Margin
60%
Country US
Market Cap 116.4B USD
Gross Margin
78%
Country US
Market Cap 104.5B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 78.7B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Cuorips Inc
Glance View

Market Cap
38B JPY
Industry
Biotechnology

Cuorips Inc is a Japan-based company mainly engaged in the development and commercialization of regenerative medical products and contract development and manufacturing organization (CDMO) business. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 46 full-time employees. The company went IPO on 2023-06-27. The main product of the Company is human iPS cell-derived cardiomyocyte sheets. The firm provides regenerative medical products for the heart and other areas through in-house research, joint research with universities and other research institutions and major pharmaceutical companies. The firm operates CDMO business using CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept.

Intrinsic Value
234.89 JPY
Overvaluation 95%
Intrinsic Value
Price
C

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
48.9%
=
Gross Profit
15.1m
/
Revenue
31m
What is the Gross Margin of Cuorips Inc?

Based on Cuorips Inc's most recent financial statements, the company has Gross Margin of 48.9%.